Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CSL has received approval from the Australian Therapeutic Goods Administration to register Panvax, the company's avian influenza vaccine.
Subscribe to our email newsletter
Developed by CSL in collaboration with the Australian government, Panvax is intended for use in the prevention of influenza caused by a pandemic strain of avian influenza virus.
CSL is said to be the only vaccine supplier that manufactures influenza vaccines in Australia. Through its recent and continuing investment of more than $80m in Fluvax (a vaccine against seasonal influenza) CSL remains committed to the ongoing provision of influenza vaccines to the Australian community.
Mary Sontrop, general manager of CSL Biotherapies, a group member company of CSL and the business unit responsible for developing and manufacturing Panvax, said: “In the event of a pandemic, CSL will rapidly gear up to manufacturing levels that will ensure all Australians have access to safe, effective coverage against avian flu. We continue to work collaboratively with the World Health Organization and with the Australian scientific community to maintain a high level of avian flu preparedness.”